- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05705869
Targeted Assessment in High-Risk paTients With dIAbetes to ideNtify Undiagnosed Heart Failure (TARTAN-HF)
Targeted Assessment in High-Risk paTients With dIAbetes to ideNtify Undiagnosed Heart Failure (TARTAN-HF)
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a prospective, multicentre, unblinded, randomised, controlled trial. The primary aim is to assess a targeted screening strategy to detect undiagnosed heart failure in high-risk patients with diabetes.
Participants will be recruited from the diabetes service in two NHS health boards in Scotland; NHS Greater Glasgow and Clyde and NHS Lanarkshire. At the point of recruitment and consent, patients will be randomised to one of two arms:
"Routine care arm" - patients in this arm will undergo routine diabetes care. They will be managed and followed up as per routine clinical care. They will be remotely monitored for HF events electronically. Quality of life questionnaires (Kansas City Cardiomyopathy Questionnaire-12 and EQ-5D) will be completed electronically through CASTOR program in this arm (with the option of paper versions for participants who can not use CASTOR).
OR
- "Investigational arm" - patients in this arm will have a blood sample taken to measure N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) using a Roche assay. In addition to this, blood samples for haemoglobin, creatinine, HbA1c, cholesterol profile, liver function tests and eGFR will be collected. Quality of life questionnaires (Kansas City Cardiomyopathy Questionnaire-12 and EQ-5D) will be completed electronically through CASTOR program in this arm (with the option of paper versions for participants who can not use CASTOR).
All patients in this arm will also have an ECG and basic body measurements and observations measured. Further venous blood samples will be collected and stored within Glasgow University storage facilities for future measurement of relevant biomarkers and for use in future ethically approved research. Urine samples will also be collected for measurement of urine albumin:creatinine ratio and for future measurement of relevant biomarkers and use in future ethically approved research.
Patients with an elevated Roche NT-proBNP (≥125 pg/mL) will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. A British Society of Echocardiography minimum dataset will be obtained, and report created.
Patients will then also undergo a handheld echocardiogram with a CE-marked handheld point of care (POC) EchoNous Kosmos echocardiogram device. The handheld echocardiogram images will be acquired by a British Society of Echocardiography accredited operator. The US2.ai algorithm (which is also CE marked) will generate an AI-automated echocardiogram report.
Patients who are classified as having heart failure (HFrEF, HFmrEF, or HFpEF) will be managed according to the latest version of European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure. The results of the cart-based echocardiogram will be used during the determination of the presence or absence of HF.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kieran F Docherty, MbChB
- Phone Number: 0141 330 2677
- Email: kieran.docherty@glasgow.ac.uk
Study Contact Backup
- Name: Mark C Petrie, MbChB
- Phone Number: 0141 330 2677
- Email: mark.petrie@glasgow.ac.uk
Study Locations
-
-
Scotland
-
Glasgow, Scotland, United Kingdom, G4 0SF
- Recruiting
- Glasgow Royal Infirmary
-
Contact:
- Kieran F Docherty, MbChB
- Phone Number: 0141 330 2677
- Email: kieran.docherty@glasgow.ac.uk
-
Contact:
- Daniel R Taylor-Sweet, MbChB
- Phone Number: 141 330 2677
- Email: daniel.taylor-sweet@ggc.scot.nhs.uk
-
Principal Investigator:
- Kieran F Docherty
-
Sub-Investigator:
- Mark C Petrie
-
Sub-Investigator:
- Ross Campbell
-
Sub-Investigator:
- Daniel R Taylor-Sweet
-
Sub-Investigator:
- John JV McMurray
-
Sub-Investigator:
- Shona Jenkins
-
Sub-Investigator:
- Brian Kennon
-
Sub-Investigator:
- Gerald McKay
-
Sub-Investigator:
- Robin Weir
-
Sub-Investigator:
- Colin Petrie
-
Glasgow, Scotland, United Kingdom, G51 4TF
- Recruiting
- Queen Elizabeth University Hospital
-
Contact:
- Kieran F Docherty, MbChB
- Phone Number: 0141 330 2677
- Email: kieran.docherty@glasgow.ac.uk
-
Principal Investigator:
- Kieran F Docherty
-
Sub-Investigator:
- Mark C Petrie
-
Sub-Investigator:
- Ross Campbell
-
Sub-Investigator:
- Daniel R Taylor-Sweet
-
Sub-Investigator:
- John JV McMurray
-
Sub-Investigator:
- Shona Jenkins
-
Sub-Investigator:
- Brian Kennon
-
Sub-Investigator:
- Gerald McKay
-
Sub-Investigator:
- Robin Weir
-
Sub-Investigator:
- Colin Petrie
-
Contact:
- Daniel R Taylor-Sweet, MbChB
- Phone Number: 0141 330 2677
- Email: daniel.taylor-sweet@glasgow.ac.uk
-
Sub-Investigator:
- Katriona Brooksbank
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female ≥40 years of age
- Informed consent
- An established diagnosis of diabetes (type 1 or type 2)
At least one additional risk factor for heart failure:
- Coronary artery disease (either a previous documented type 1 myocardial infarction or coronary artery bypass grafting or percutaneous coronary intervention or documented stenosis of an epicardial coronary artery [50% left main or >70% left anterior descending, circumflex or right coronary artery])
- Persistent or permanent atrial fibrillation (not paroxysmal atrial fibrillation)
- Previous ischemic or embolic stroke
- Peripheral arterial disease (previous surgical or percutaneous revascularisation or a documented stenosis greater than 50% of a major peripheral arterial vessel).
- Chronic kidney disease (defined as an estimated glomerular filtration rate <60mL/min/1.73m2 or eGFR 60-90mL/min/1.73m2 and UACR >300mg/g).
- Regular loop diuretic use (any dose at any dosing interval) for >30 days.
- COPD (evidenced by one of the following; PFTs showing airway obstruction, diagnosis by respiratory physician, CT scan reporting presence of emphysema or treatment with national guideline-advocated COPD therapy).
Exclusion criteria:
- Inability to give informed consent e.g., due to significant cognitive impairment.
- Previous documented diagnosis of heart failure.
- Currently receiving scheduled renal replacement therapy.
- Anyone who, in the investigators' opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise survival over the study period
Exclusion Criteria:
- Inability to give informed consent e.g., due to significant cognitive impairment.
- Previous documented diagnosis of heart failure.
- Currently receiving scheduled renal replacement therapy.
- Anyone who, in the investigators' opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise survival over the study period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SCREENING
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Routine care arm
Patients in this arm will undergo routine diabetes care.
They will be managed and followed up as per routine clinical care.
They will be remotely monitored for heart failure events electronically.
Quality of life questionnaires (Kansas City Cardiomyopathy Questionnaire-12 and EQ-5D) will be collected.
|
|
EXPERIMENTAL: Investigational arm
Patients in this arm will have a blood sample taken to measure N-terminal prohormone of B-type natriuretic peptide (NT-proBNP). In addition to this, routine blood samples, an ECG, body measurements, patient reported outcomes and observations will be recorded. Further blood and urine samples will be collected and stored within Glasgow University storage facilities for future measurement of relevant biomarkers and for use in future ethically approved research. Patients with an elevated NT-proBNP (≥125 pg/mL) will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. Patients will then also undergo a handheld echocardiogram with a CE-marked handheld point of care EchoNous Kosmos echocardiogram device. Patients who are classified as having heart failure (HFrEF, HFmrEF, or HFpEF) will be managed according to the latest version of European Society of Cardiology guidelines. |
NT-proBNP will be measured in all participants in the Investigational arm.
If the level of the NT-proBNP is elevated (≥125pg/mL) participants will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment.
Participants with HF identified will be referred to their local HF clinic for ongoing management.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Diagnosis of heart failure within 6 months
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Diagnosis of HFrEF within 6 months
Time Frame: 6 months
|
6 months
|
People diagnosed with HFrEF receiving GDMT within 6 months
Time Frame: 6 months
|
6 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
All-cause mortality at 1 year
Time Frame: 1 year
|
1 year
|
Diagnosis of HFmrEF within 6 months
Time Frame: 6 months
|
6 months
|
Diagnosis of HFpEF within 6 months
Time Frame: 6 months
|
6 months
|
People diagnosed with HFmrEF and HFpEF receiving SGLT2i therapy within 6 months
Time Frame: 6 months
|
6 months
|
Diagnosis of asymptomatic left ventricular dysfunction (LVEF≤40%) within 6 months
Time Frame: 6 months
|
6 months
|
Time to first heart failure hospitalisation at 1 year
Time Frame: 1 year
|
1 year
|
Time to first heart failure hospitalisation at 2 years
Time Frame: 2 years
|
2 years
|
Time to first heart failure hospitalisation at 5 years
Time Frame: 5 years
|
5 years
|
All-cause mortality at 2 years
Time Frame: 2 years
|
2 years
|
All-cause mortality at 5 years
Time Frame: 5 years
|
5 years
|
Time to first occurence of any components of the following clinical composite 1) heart failure hospitalisation 2) all-cause mortality at 1 year
Time Frame: 1 year
|
1 year
|
Time to first occurence of any components of the following clinical composite 1) heart failure hospitalisation 2) all-cause mortality at 2 years
Time Frame: 2 years
|
2 years
|
Time to first occurence of any components of the following clinical composite 1) heart failure hospitalisation 2) all-cause mortality at 5 years
Time Frame: 5 years
|
5 years
|
The incremental cost-effectiveness ratio (ICER) will be expressed as incremental costs/life-year gained
Time Frame: 5 years
|
5 years
|
he accuracy of handheld echocardiography with AI-automated reporting compared to full cart-based echocardiogram and manual reporting for the measurement of LVEF (%)
Time Frame: 6 months
|
6 months
|
The number of patients in the NT-proBNP/echocardiography group with echocardiographic features of potential amyloid as assessed by the US2.ai algorithm report conclusion of "amyloid to be considered"
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mark C Petrie, MbChB, University of Glasgow
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GN22CA228
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on NT-proBNP
-
Mayo ClinicCompletedPregnancy Complications | Congenital Heart DiseaseUnited States
-
Sohag UniversityNot yet recruiting
-
General Hospital Murska SobotaRoche Pharma AG; Slovenian Research Agency; Murska Sobota Municipiality; Community...Unknown
-
University of ValenciaCompleted
-
Hospital Universitario Virgen de la ArrixacaJuan Cinca Cuscullola; Pablo García Pavía; Manuel Martinez Selles; Antoni Bayés... and other collaboratorsCompletedHeart Failure | Preserved Left Ventricular Ejection FractionSpain
-
NHS Greater Glasgow and ClydeKarolinska University Hospital; University of British Columbia; Uppsala University and other collaboratorsRecruitingCardiovascular Diseases | Heart FailureUnited States, Sweden, Canada, Denmark, United Kingdom
-
Washington University School of MedicineUniversity of Abuja Teaching HospitalCompletedHypertensive Disorder of PregnancyNigeria
-
The University of Hong KongUnknown
-
Unity Health TorontoHoffmann-La RocheUnknownCongestive Heart FailureCanada
-
University of CataniaCompleted